Head to Head Survey: REGENXBIO (NASDAQ:RGNX) & Pluri (NASDAQ:PLUR)

REGENXBIO (NASDAQ:RGNX) and Pluri (NASDAQ:PLUR) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, risk, dividends, institutional ownership, analyst recommendations, earnings and valuation.

Profitability

This table compares REGENXBIO and Pluri’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
REGENXBIO	-112.58%	-220.07%	-46.04%
Pluri	-2,344.59%	N/A	-82.71%

Analyst Recommendations

This is a breakdown of current ratings and target prices for REGENXBIO and Pluri, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
REGENXBIO	1	3	9	1	2.71
Pluri	1	0	0	0	1.00

REGENXBIO currently has a consensus target price of $23.17, indicating a potential upside of 224.01%. Given REGENXBIO’s stronger consensus rating and higher possible upside, equities analysts clearly believe REGENXBIO is more favorable than Pluri.

Valuation & Earnings

This table compares REGENXBIO and Pluri”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
REGENXBIO	$170.44 million	2.77	-$193.88 million	($3.79)	-1.89
Pluri	$1.02 million	10.55	-$23.82 million	($2.45)	-0.35

Pluri has lower revenue, but higher earnings than REGENXBIO. REGENXBIO is trading at a lower price-to-earnings ratio than Pluri, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

88.1% of REGENXBIO shares are owned by institutional investors. Comparatively, 16.6% of Pluri shares are owned by institutional investors. 14.2% of REGENXBIO shares are owned by insiders. Comparatively, 43.2% of Pluri shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Volatility & Risk

REGENXBIO has a beta of 1.13, indicating that its share price is 13% more volatile than the S&P 500. Comparatively, Pluri has a beta of 0.69, indicating that its share price is 31% less volatile than the S&P 500.

Summary

REGENXBIO beats Pluri on 9 of the 15 factors compared between the two stocks.

About REGENXBIO

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.

About Pluri

Pluri Inc., a biotechnology company, engages in the development of placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions. It operates in the field of regenerative medicine, food-tech, and biologics and focuses on establishing partnerships that leverage its 3D cell-based technology to additional industries that require mass cell production. The company's development pipeline includes PLX-PAD, is composed of maternal mesenchymal stromal cells originating from the placenta that is currently under phase III study for orthopedic, phase II study for COVID-19, and phase I/II clinical study for Steroid-Refractory cGVHD indications; and PLX-R18, is composed of fetal MSC like cells originating from the placenta that is currently under phase I study for HCT and pilot study for ARS indications. It is also involved in the development of modified PLX cells. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.